Vaccine
The vaccines are supplied by the JSC National Immunobiological company within the frames of implementing the National calendar of prophylactic immunization. The influenza prevention vaccines are produced by the companies affiliated to the holding company Nacimbio – NPO Microgen and LLC FORT.
- During the epidemics 10 – 20% of the whole population and up to 40 – 60% of elderly people are affected
- Annually influenza becomes the reason of 250-500 thousand deaths and 3 – 5 million cases of serious diseases
- age: children younger than 6 years, people older than 65 years
- chronic cardio – vascular diseases
- respiratory diseases
- chronic renal failure
- immunodeficient disease
Twice a year the WHO updates its recommendations regarding the composition of antigens of the influenza virus strains for the new epidemic season. In the season of 2016 – 2017 the tri-valent vaccines (the winter season in the Northern hemisphere) must contain two subtypes A and one subtype B of the influenza viruses. Based on these recommendations Nacimbio has developed the new effective vaccines.
is a vaccine produced by NPO Microgen meant for the active annual prophylactic immunization against the seasonal influenza. The preservative-free version is used in children from 6 months of age, adolescents and adults with no age limit; the vaccine with preservative is used in adults aged 18+. The vaccine is made at the production facilities of NPO Microgen by the fully integrated cycle. This vaccine is supplied within the frames of the National calendar of prophylactic immunization.
is an anti-influenza vaccine manufactured by the company FORT by the fully integrated technological cycle and meeting the requirements and norms of GMP. It is approved for immunization of children from 6 years and older, without age limitations. This vaccine is supplied within the frames of the National calendar of prophylactic immunization.
